AI Product

Anumana — Digital Health

ECG-AI software-as-a-medical-device algorithms analyzing standard 12-lead ECG waveforms to detect low ejection fraction, pulmonary hypertension, cardiac amyloidosis, and additional cardiovascular…

Intelligence Summary

Product
  • Active
  • Verified public sources
  • Developer Anumana
  • Category Digital Health
  • Status Active
  • Latest update 2021: Anumana founded in Cambridge by nference and Mayo Clinic; Murali Aravamudan is executive chairman.
  • Documentation Official page
  • Last reviewed Jul 2026
5 Technologies

Official product page

Target customer

Health systems, cardiologists, and primary care networks performing high-volume ECGs who need early detection of heart failure risk, pulmonary hypertension, and amyloidosis without adding separate diagnostic tests at point of care.

Features & capabilities

Industries: AI in Healthcare; Digital Health

Related reports

Related insights

Overview

ECG-AI software-as-a-medical-device algorithms analyzing standard 12-lead ECG waveforms to detect low ejection fraction, pulmonary hypertension, cardiac amyloidosis, and additional cardiovascular conditions in development.

Product and company

Anumana — Digital Health is a verified product offering linked to the Brel Digital company profile for Anumana.

Use cases

ECG-AI software-as-a-medical-device algorithms analyzing standard 12-lead ECG waveforms to detect low ejection fraction, pulmonary hypertension, cardiac amyloidosis, and additional cardiovascular conditions in development.

Target customer

Health systems, cardiologists, and primary care networks performing high-volume ECGs who need early detection of heart failure risk, pulmonary hypertension, and amyloidosis without adding separate diagnostic tests at point of care.

Technologies

Primary technologies assigned from the linked company profile: Deep Learning, Healthcare Analytics, Machine Learning, Medical Imaging, Predictive Analytics.

Sources and references

  • Official product / company source: https://anumana.ai/news/anumana-receives-first-and-only-fda-clearance-for-ecg-ai-cardiac-amyloidosis-algorithm-using-a/
  • Supporting source: https://www.anumana.ai/about-us/

Product facts are limited to information already verified on the linked Brel company profile and its cited official URLs. No speculative capabilities are added.

Last reviewed

This product profile was last reviewed on 2026-07-14.

Correction request

If this product record is inaccurate or outdated, submit a correction through Brel Digital’s Corrections Policy.

Features and capabilities

  • ECG-AI software-as-a-medical-device algorithms analyzing standard 12-lead ECG waveforms to detect low ejection fraction, pulmonary hypertension, cardiac amyloidosis, and additional cardiovascular conditions in development.

Extracted from the linked company product description already verified on Brel. No capabilities were invented.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

Enquire about this product profile

Messages are delivered to contact@breldigital.com.